株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

補助人工心臓(VAD)の世界市場 - 成長、動向、予測(2019年~2024年)

Ventricular Assist Device Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 910289
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
補助人工心臓(VAD)の世界市場 - 成長、動向、予測(2019年~2024年) Ventricular Assist Device Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年09月01日 ページ情報: 英文 115 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界の補助人工心臓(VAD)市場は、2019年から2024年にかけて約7.23%のCAGRで成長すると予測されています。

当レポートでは、世界の補助人工心臓(VAD)市場を調査し、市場の概要、タイプ・用途・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 心疾患と心不全の負担の増大
    • 心臓病管理用デバイスの技術的進歩
    • 心血管疾患の認知度の向上とイニシアチブの増加
  • 市場の阻害要因
    • 医療機器および処置のコストの高さ
    • 補助人工心臓に関連するリスク
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • タイプ別
    • 左心室補助装置(LVAD)
    • 右心室補助装置(RVAD)
    • 両心室補助装置(BIVAD)
  • 用途別
    • 心臓移植までの橋渡し治療 (BTT)
    • 長期在宅治療 (DT)
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abiomed Inc.
    • BiVACOR Inc.
    • Abbott Laboratories
    • Berlin Heart GmbH
    • Calon Cardio
    • Jarvik Heart Inc.
    • MAQUET Holding BV & Co. KG
    • Medtronic PLC
    • SynCardia Systems LLC
    • テルモ

第7章 市場機会および将来動向

目次
Product Code: 50887

Market Overview

The Ventricular Assist Device Market studied is anticipated to grow with a CAGR of about 7.23%, during the forecast period (2019-2024).

The major factors attributing to the growth of the ventricular assist device market are technological advancement of devices for cardiac diseases management, growing initiatives and awareness regarding cardiovascular diseases, and majorly the growing burden of cardiac diseases and heart failure is driving the market. Because the global high burden of cardiac diseases and heart failures has been one of the major factors for the growing demand and growth of the global ventricular assist device market. VAD implantations are lifesaving equipment for patients with severe heart failure. They are useful in minimizing the symptoms of heart failure, helping patients to resume their daily activities. The coronary heart diseases associated with hypertension are a very common cause of chronic heart failure. Apart from that other cardiac conditions, such as ischaemic and dilated cardiomyopathies, also require a significant level of surgical interventions. For all the patient cases requiring advanced heart failure-related therapy, the heart transplantation is a long-term successful procedure. However, due to less availability of organs, the waiting time increases more than six months. Such cases require the immediate assistance of VAD, which acts as a bridge to transplantation. Here, the demand and availability of VAD play a critical role, and thus, the growing burden of cardiac diseases and heart failure is a major force to propelling the VAD market at the global level. However, there are also risks involved in the VAD implant, hence these risks are showing an impact on the market growth.

Scope of the Report

Ventricular assist devices (VAD) are highly important for patients with weakened hearts or heart failures. They are used to temporarily maintain the heart function, until the heart recovers, or before the heart transplant. In some chronic heart conditions, they are used as permanent support therapy, as they are mechanical pumps that are surgically implanted on the heart to pump blood in the whole body.

Key Market Trends

Left Ventricular Assist Device (LVAD) is Expected to Hold the Major Share in the Type of Ventricular Device Segment

LVAD is implanted during an open heart surgery, where it receives blood from the left ventricle and delivers it to the aorta. It works along with the patient's own heart. It is mostly given as a treatment option for patients with end-stage heart failure. There are a number of international hospitals and research centers that widely use VAD programs since the past two decades, particularly in the developed markets as well as for help in new investigational devices. Abbott (Thoratec), Berlin Heart, and Medtronic are among the top players in this segment mostly that are well established in the developed market. In contrast to developed markets, a restricted percentage of usage in the emerging markets has been observed, such as operation in restricted cities of China and India. Further, with the increased utilization of durable mechanical support devices, it is important for all emergency departments of hospitals to have a well-written protocol to provide optimal care for patients with VADs.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The presence of high per capita healthcare expenditure, coupled with the raising prevalence of cardiac diseases is expected to propel the high growth of the ventricular assist device in the North American region. In the North America region, the US holds the highest share. This is due to the presence of a large population with heart disease. In the United States, cardiovascular diseases and hypertension cases account for a major share of the people that require surgery. A large number of cardiac considerations and systemic considerations are taken into account, as there are several factors associated with preoperative, perioperative, and postoperative complications. The high burden of patients with heart failure-related indications is mostly above the age of 40, which majorly boosts the demand of VAD in hospitals and clinics. As per the American Heart Association (AHA) Heart Disease and Stroke Statistics, 2017, heart failure affected an estimated 6.5 million people in the United States.

Competitive Landscape

The ventricular assist device market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising geriatric population and high prevalence of diseases, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are Abiomed Inc., BiVACOR Inc, Abbott Laboratories (St. Jude Medical Inc.), Medtronic PLC, and Terumo Corporation are among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cardiac Diseases and Heart Failure
    • 4.2.2 Technological Advancement of Devices for Cardiac Diseases Management
    • 4.2.3 Growing Initiatives and Awareness Regarding Cardiovascular Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices and Procedures
    • 4.3.2 Several Risks Associated to VAD Implant
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Ventricular Device
    • 5.1.1 Left Ventricular Assist Device (LVAD)
    • 5.1.2 Right Ventricular Assist Device (RVAD)
    • 5.1.3 Biventricular Assist Device (BIVAD)
  • 5.2 By Application
    • 5.2.1 Bridge-to-transplant (BTT) therapy
    • 5.2.2 Destination therapy
    • 5.2.3 Other Therapies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abiomed Inc.
    • 6.1.2 BiVACOR Inc.
    • 6.1.3 Abbott Laboratories (St. Jude Medical Inc.)
    • 6.1.4 Berlin Heart GmbH
    • 6.1.5 Calon Cardio
    • 6.1.6 Jarvik Heart Inc.
    • 6.1.7 MAQUET Holding BV & Co. KG
    • 6.1.8 Medtronic PLC
    • 6.1.9 SynCardia Systems LLC
    • 6.1.10 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS